Clinical Trial Results:
Reversal of steroid insensitivity in COPD by theophylline
Summary
|
|
EudraCT number |
2006-003561-13 |
Trial protocol |
GB |
Global end of trial date |
29 Aug 2007
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Dec 2019
|
First version publication date |
02 Dec 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
cro488
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00241631 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Imperial College London
|
||
Sponsor organisation address |
South Kensington, London, United Kingdom, SW7 2AZ
|
||
Public contact |
Ian Adcock, Imperial College London, ian.adcock@imperial.ac.uk
|
||
Scientific contact |
Ian Adcock, Imperial College London, ian.adcock@imperial.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Aug 2008
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
29 Aug 2007
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
29 Aug 2007
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Does the addition of low dose theophylline restore the anti-inflammatory effects of steroids?
|
||
Protection of trial subjects |
None
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
03 Apr 2006
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 49
|
||
Worldwide total number of subjects |
49
|
||
EEA total number of subjects |
49
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
24
|
||
From 65 to 84 years |
25
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Forty-nine theophylline-naive (Global Initiative for Chronic Obstructive Lung Disease stage 2 or 3) patients with COPD were recruited, between April 2006 and August 2007. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Forty-nine theophylline-naive (Global Initiative for Chronic Obstructive Lung Disease stage 2 or 3) patients with COPD were recruited. Thirty completed the trial and were suitable for analysis. | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Run in (2 Weeks)
|
||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Arm title
|
All participants | ||||||||||||||||||||||||
Arm description |
Run in period, no intervention | ||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||
Period 2 title |
Phase 1 (4 Weeks)
|
||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||
Arm description |
participants received placebo | ||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||
Routes of administration |
Inhalation use
|
||||||||||||||||||||||||
Dosage and administration details |
Single dose for four weeks
|
||||||||||||||||||||||||
Investigational medicinal product name |
Theophylline Placebo
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Single dose for four weeks
|
||||||||||||||||||||||||
Arm title
|
Steroid | ||||||||||||||||||||||||
Arm description |
placebo theophylline capsules and inhaled fluticasone propionate (FP) (500 mg bid ) | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Fluticasone propionate (FP) (500 mg bid )
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||
Routes of administration |
Inhalation use
|
||||||||||||||||||||||||
Dosage and administration details |
500 mg bid for four weeks
|
||||||||||||||||||||||||
Investigational medicinal product name |
Theophylline Placebo
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Single dose for four weeks
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Period 3
|
|||||||||||||||||||||||||
Period 3 title |
Wash Out (2 Weeks)
|
||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Arm title
|
All participants | ||||||||||||||||||||||||
Arm description |
wash out period, no intervention | ||||||||||||||||||||||||
Arm type |
No intervention | ||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Period 4
|
|||||||||||||||||||||||||
Period 4 title |
Phase 2 (4 Weeks)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes [1] | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||
Arm description |
Participants received placebo | ||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||
Investigational medicinal product name |
Theophylline Active
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Single dose for four weeks
|
||||||||||||||||||||||||
Arm title
|
Steroid | ||||||||||||||||||||||||
Arm description |
- | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Theophylline Active
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
Single dose for four weeks
|
||||||||||||||||||||||||
Notes [1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period. Justification: The baseline characteristics are only for the participants who completed the study. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Notes [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: The baseline characteristics are only for the participants who completed the study. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received placebo | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Steroid
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
All participants
|
||
Reporting group description |
Run in period, no intervention | ||
Reporting group title |
Placebo
|
||
Reporting group description |
participants received placebo | ||
Reporting group title |
Steroid
|
||
Reporting group description |
placebo theophylline capsules and inhaled fluticasone propionate (FP) (500 mg bid ) | ||
Reporting group title |
All participants
|
||
Reporting group description |
wash out period, no intervention | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants received placebo | ||
Reporting group title |
Steroid
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
Sputum Inflammatory Cell Counts | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
10 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Sputum Inflammatory Cell Counts | ||||||||||||
Comparison groups |
Placebo v Steroid
|
||||||||||||
Number of subjects included in analysis |
30
|
||||||||||||
Analysis specification |
Post-hoc
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.012 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Interleukin 8 (IL8) | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
10 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Interleukin 8 (IL8) | ||||||||||||
Comparison groups |
Placebo v Steroid
|
||||||||||||
Number of subjects included in analysis |
30
|
||||||||||||
Analysis specification |
Post-hoc
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Total Sputum Eosinophils | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
10 weeks
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Total Sputum Eosinophils | ||||||||||||
Comparison groups |
Placebo v Steroid
|
||||||||||||
Number of subjects included in analysis |
30
|
||||||||||||
Analysis specification |
Post-hoc
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Confidence interval |
|
||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||
Timeframe for reporting adverse events |
10 weeks
|
|||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||
Dictionary version |
10.0
|
|||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||
Reporting group description |
Participants received placebo | |||||||||||||||||||||
Reporting group title |
Steroid
|
|||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||
|
||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/20299628 http://www.ncbi.nlm.nih.gov/pubmed/15888697 |